Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

KIERNAN ROBERT J

2. Issuer Name and Ticker or Trading Symbol
Global Medical REIT Inc. [GMRE]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Financial Officer

(Last)

(First)

(Middle)

2 BETHESDA METRO CENTER, SUITE 440

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2018

(Street)

BETHESDA, MD 20814

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

LTIP Unit (Right to Buy) ⁽¹⁾

⁽²⁾

03/05/2018⁽³⁾

2,225 ⁽³⁾

⁽²⁾

Common Stock

2,225

$ 0

8,199

LTIP Unit (Right to Buy) ⁽⁴⁾

⁽²⁾

03/05/2018⁽⁴⁾

19,727 ⁽⁴⁾

⁽²⁾

Common Stock

19,727

$ 0

27,926

LTIP Unit (Right to Buy) ⁽⁵⁾

⁽²⁾

03/05/2018⁽⁵⁾

9,469 ⁽⁵⁾

⁽²⁾

Common Stock

9,469

$ 0

37,395

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
KIERNAN ROBERT J 2 BETHESDA METRO CENTER, SUITE 440 BETHESDA, MD 20814			Chief Financial Officer

Signatures

/s/ Robert Kiernan		03/07/2018
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined on March 5, 2018 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of December 31, 2017 and 50% of the LTIP Units will vest on December 31, 2018, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.
(2)	As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date.
(3)	Awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.2 to the Issuer's Current Report on Form 8-K filed on March 6, 2017.
(4)	Represents LTIP Units in the OP granted as a retention award. The Issuer's Board of Directors determined on March 5, 2018 that 50% of the LTIP Units will vest on March 5, 2020 and 50% of the LTIP Units will vest on March 5, 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.
(5)	LTIP Units vest in equal one-third installments on March 5 of 2019, 2020 and 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.